ACAT2: A Potential Drug Target and Biomarker for Acetyl-CoA Transferase-Like Protein

Target Name: ACAT2

NCBI ID: G39

ACAT2

ACAT2: A Potential Drug Target and Biomarker for Acetyl-CoA Transferase-Like Protein

Abstract

Acetyl-CoA transferase-like protein (ACAT2) is a protein that plays a crucial role in the metabolism of acetyl-CoA, a key intermediate in the citric acid cycle. Several studies have identified ACAT2 as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and metabolic disorders. In this article, we will review the current research on ACAT2 and its potential as a drug target and biomarker.

The citric acid cycle, also known as the Krebs cycle or tricarboxylic acid (TCA) cycle, is a central metabolic pathway that generates energy in the form of ATP from a large molecule of acetyl-CoA, which is produced from the food we consume. The TCA cycle is a critical pathway for the production of energy in the human body and is also involved in the synthesis of various molecules, including amino acids, nucleotides, and lipids.

One of the key enzymes in the TCA cycle is ACAT2, which is a protein that plays a crucial role in the transfer of acetyl-CoA from the cytoplasm to the mitochondrial matrix. transferase-like protein (ACAT2) is a protein that plays a crucial role in the metabolism of acetyl-CoA, a key intermediate in the citric acid cycle.

Diseases associated with ACAT2

Several studies have identified ACAT2 as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and metabolic disorders.

1. Cancer

Studies have shown that ACAT2 is highly expressed in various types of cancer, including breast, ovarian, and prostate cancer. Additionally, ACAT2 has been shown to be involved in the regulation of cell growth and apoptosis, which are important factors in cancer development.

2. Neurodegenerative diseases

ACAT2 has also been shown to be involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Studies have shown that ACAT2 is involved in the production of amyloid, a hallmark protein associated with the development of Alzheimer's disease, and that it plays a role in the regulation of neurogenesis, which is important for the development of new neurons.

3. Metabolic disorders

ACAT2 has also been shown to be involved in the metabolism of various nutrients, including carbohydrates, lipids, and proteins. Studies have shown that ACAT2 is involved in the metabolism of saturated fatty acids, which are a major source of these nutrients. Additionally, ACAT2 has been shown to be involved in the regulation of insulin sensitivity, which is important for the development of metabolic disorders.

Conclusion

In conclusion, ACAT2 is a protein that plays a crucial role in the metabolism of acetyl-CoA, a key intermediate in the citric acid cycle. Several studies have identified ACAT2 as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and metabolic disorders. Further research is needed to fully understand the role of ACAT2 in these diseases and to develop effective treatments.

Protein Name: Acetyl-CoA Acetyltransferase 2

Functions: Involved in the biosynthetic pathway of cholesterol

The "ACAT2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ACAT2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets